Last updated: 24 July 2019 at 10:33pm EST

Elliot Sigal Net Worth

The estimated Net Worth of Elliot Sigal is at least $27.1 Million dollars as of 12 October 2017. Elliot Sigal owns over 29 units of Bristol-Myers Squibb Co stock worth over $546,297 and over the last 16 years Elliot sold BMY stock worth over $26,536,658.

Elliot Sigal BMY stock SEC Form 4 insiders trading

Elliot has made over 20 trades of the Bristol-Myers Squibb Co stock since 2009, according to the Form 4 filled with the SEC. Most recently Elliot bought 29 units of BMY stock worth $2,632 on 12 October 2017.

The largest trade Elliot's ever made was selling 506,507 units of Bristol-Myers Squibb Co stock on 29 April 2013 worth over $20,113,393. On average, Elliot trades about 63,768 units every 86 days since 2008. As of 12 October 2017 Elliot still owns at least 11,243 units of Bristol-Myers Squibb Co stock.

You can see the complete history of Elliot Sigal stock trades at the bottom of the page.

Insiders trading at Bristol-Myers Squibb Co

Over the last 17 years, insiders at Bristol-Myers Squibb Co have traded over $318,151,721 worth of Bristol-Myers Squibb Co stock and bought 211,503 units worth $6,601,565 . The most active insiders traders include Lamberto Andreotti, James M Cornelius, and Giovanni Caforio. On average, Bristol-Myers Squibb Co executives and independent directors trade stock every 8 days with the average trade being worth of $1,682,720. The most recent stock trade was executed by Cari Gallman on 1 August 2024, trading 1,061 units of BMY stock currently worth $51,554.

What does Bristol-Myers Squibb Co do?

The Bristol-Myers Squibb Company is an American multinational pharmaceutical company. Headquartered in New York City, BMS is one of the worlds largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2022, it had a total revenue of $46.2 billion.

Complete history of Elliot Sigal stock trades at Bristol-Myers Squibb Co

Insider	Trans. Transaction	Total value
Elliot Sigal EVP, CSO, President R, and D	Option	$2,670,614 3 Jun 2013
Elliot Sigal EVP, CSO, President R, and D	Option	$4,494,263 30 May 2013
Elliot Sigal EVP, CSO, President R, and D	Sale	$20,113,393 29 Apr 2013
Elliot Sigal EVP, CSO, President R, and D	Option	$4,968,597 7 Mar 2013
Elliot Sigal EVP, CSO, President R, and D	Option	$1,999,339 3 Mar 2013
Elliot Sigal EVP, CSO, President R, and D	Option	$5,537,166 8 Feb 2013
Elliot Sigal EVP, CSO, President R, and D	Sale	$5,189,481 27 Nov 2012
Elliot Sigal EVP, CSO, President R, and D	Option	$2,774,884 6 Mar 2012
Elliot Sigal EVP, CSO, President R, and D	Option	$2,532,668 1 Mar 2012
Elliot Sigal EVP, CSO, President R, and D	Option	$12,830,059 16 May 2011
Elliot Sigal EVP, CSO, President R, and D	Option	$378,663 4 Mar 2011
Elliot Sigal EVP, CSO, President R, and D	Option	$306,254 2 Mar 2011
Elliot Sigal EVP, CSO, President R, and D	Option	$2,967,280 1 Mar 2011
Elliot Sigal EVP, CSO, President R, and D	Sale	$1,233,784 15 Mar 2010
Elliot Sigal EVP, CSO, President R, and D	Option	$173,800 6 Mar 2010
Elliot Sigal EVP, CSO, President R, and D	Option	$1,780,903 2 Mar 2010
Elliot Sigal EVP, CSO, President R, and D	Sale	$323,666 23 Dec 2009
Elliot Sigal EVP, CSO, President R, and D	Buy	$287,700 30 Apr 2009

Bristol-Myers Squibb Co executives and stock owners

Bristol-Myers Squibb Co executives and other stock owners filed with the SEC include:

Giovanni Caforio,
Chairman of the Board, Chief Executive Officer
Sandra Leung,
Executive Vice President, General Counsel
Dr. Giovanni Caforio M.D.,
Chairman & CEO
Christopher Boerner,
Executive Vice President and Chief Commercial Officer
David Elkins,
Executive Vice President and Chief Financial Officer Member of the Leadership Team
Rupert Vessey,
Executive Vice President, Research and Early Development Member of the Leadership Team
Louis Schmukler,
Executive Vice President, President - Global Product Development and Supply
David V. Elkins,
Exec. VP & CFO
Rupert Vessey BCH, BM, DPHIL, M.A.,
Exec. VP and Pres of Research & Early Devel.
Sandra Leung Esq.,
Exec. VP & Gen. Counsel
Dr. Christopher S. Boerner,
Exec. VP & Chief Commercialization Officer
Vicki Sato,
Lead Independent Director
Matthew Emmens,
Independent Director
Peter Arduini,
Independent Director
Dinesh Paliwal,
Independent Director
Theodore Samuels,
Independent Director
Karen Vousden,
Independent Director
Robert Bertolini,
Independent Director
Gerald Storch,
Independent Director
Phyllis Yale,
Independent Director
Julia Haller,
Independent Director
Michael Bonney,
Independent Director
Derica Rice,
Independent Director
Paula Price,
Independent Director
Tim Power,
Vice President of Investor Relations
Joseph Eid,
Senior Vice President and Head of Global Medical Affairs Member of the Leadership Team
Karen Santiago,
Senior Vice President, Corporate Controller
Adam Dubow,
Senior Vice President, Chief Compliance Officer and Ethics Officer
Paul von Autenried,
Chief Information Officer, Senior Vice President
Elizabeth Mily,
Executive Vice President - Strategy & Business Development
Kathryn Metcalfe,
Executive Vice President - Corporate Affairs Member of the Leadership Team
Samit Hirawat,
Executive Vice President, Chief Medical Officer, Global Drug Development Member of the Leadership Team
Nadim Ahmed,
Executive Vice President and President - Hematology
John Elicker,
Executive Vice President of Investor Relations
Ann Judge,
Chief Human Resource Officer, Senior Vice President Member of the Leadership Team
Ann M. Powell Judge,
Exec. VP & Chief HR Officer
Adam Dubow,
Sr. VP, Chief Compliance & Ethics Officer
Timothy Power,
VP & Head of Investor Relations
Paul von Autenried,
Exec. VP & Chief Information Officer
Greg Meyers,
Exec. VP and Chief Digital & Technology Officer
Jose Baselga,
Director
Alan J Lacy,
Director
Joseph C Caldarella,
VP & Financial Controller
Anne Nielsen,
Chief Compliance & Ethics Off
Laurie H M.D. Glimcher,
Director
Michael Grobstein,
Director
Togo D Jr West,
Director
Emmanuel Blin,
SVP, Head of Commercialization
Francis M Cuss,
SVP Dscvry & Exp Clinl Resrch
Murdo Gordon,
SVP, Head of Worldwide Markets
Thomas J. Jr. Lynch,
Director
Karin Shanahan,
EVP, Glob. Prod. Dev. & Supply
Lynelle Hoch,
President, Cell Therapy Org.
Phil M Holzer,
SVP and Controller
Ahn Amanda Poole,
EVP, Chief Human Resources
Samuel J Moed,
SVP, Strat Plan & Analysis
Michelle Weese,
EVP, Corporate Affairs
Paul Biondi,
SVP, Head of Strategy & BD
Charles A Bancroft,
EVP, Head of Integration
Ann Powell,
EVP, Chief Human Resources
Frances K Heller,
SVP, Business Development
Brian Daniels,
SVP Global Development
Elliot Sigal,
EVP, CSO & President R&D
Beatrice J Cazala,
SVP Comm Ops & Pres GC Euro EM
Robert T Zito,
SVP & Chief Comm Officer
Jeremy M Levin,
SVP Strat Transactions
R Sanders Williams,
Director
Anthony C Hooper,
President US Pharmaceuticals
Louis J Freeh,
Director
Anthony A Mcbride,
SVP Human Resources
De Notaristefani Carlo,
President, Tech Ops
Leif Johansson,
Director
John E Celentano,
SVP Strat & Productivity Trans
Jean Marc Huet,
SVP & CFO
James M Cornelius,
Chairman & CEO
Lewis B Campbell,
Director
Medina Manuel Hidalgo,
Director
Benjamin Hickey,
President, RayzeBio Org.
Gregory Scott Meyers,
EVP, Chief Digital & Tech Off.
Sharon Greenlees,
SVP & Controller
Deepak Bhatt,
Director
Michael R. Mc Mullen,
Director
Adam Lenkowsky,
EVP, Chief Commercial Officer
Robert M Plenge,
EVP, Chief Research Officer
Cari Gallman,
EVP, Corporate Affairs